C.M. Bidwell & Associates’s AtriCure ATRC Stock Holding History

C.M. Bidwell & Associates’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-117	Closed	-$3.34K	–	503
2026 Q1	$3.34K	Hold	117	–	–	﹤0.01%	369
2025 Q4	$4.63K	Buy	117 +1	+0.9%	+$37	﹤0.01%	337
2025 Q3	$4.09K	Hold	116	–	–	﹤0.01%	352
2025 Q2	$3.8K	Hold	116	–	–	﹤0.01%	348
2025 Q1	$3.74K	Buy	+116	New	+$4.31K	﹤0.01%	341

Other funds holding ATRC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

C.M. Bidwell & Associates's ATRC Position: Q2 2026 in Review

C.M. Bidwell & Associates sold out of AtriCure (ATRC) in Q2 2026, closing a stake of 117 shares — an estimated $3.34K sold.

C.M. Bidwell & Associates first reported a position in ATRC in Q1 2025 and held it in 5 quarters. The position peaked at $4.63K in Q4 2025. 251 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

C.M. Bidwell & Associates reported no remaining AtriCure position as of Q2 2026 after selling out during the quarter.
C.M. Bidwell & Associates sold 117 AtriCure shares in Q2 2026, an estimated $3.34K.
C.M. Bidwell & Associates first reported a position in AtriCure in Q1 2025 and held it in 5 quarters.
C.M. Bidwell & Associates's AtriCure position peaked at $4.63K in Q4 2025.
251 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.